BS_B1C6GZ84
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 6.5374507227332455
- age_years
- 8.315
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.715
- G2M_CHECKPOINT+0.672
- MYC_TARGETS_V2+0.645
- MYC_TARGETS_V1+0.603
- MTORC1_SIGNALING+0.312
- DNA_REPAIR+0.301
- UNFOLDED_PROTEIN_RESPONSE+0.279
- MITOTIC_SPINDLE+0.275
- INTERFERON_ALPHA_RESPONSE+0.223
- CHOLESTEROL_HOMEOSTASIS+0.175
Top 10 suppressed
- P53_PATHWAY-0.352
- XENOBIOTIC_METABOLISM-0.328
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.323
- BILE_ACID_METABOLISM-0.313
- TNFA_SIGNALING_VIA_NFKB-0.304
- INFLAMMATORY_RESPONSE-0.289
- HEME_METABOLISM-0.285
- MYOGENESIS-0.275
- APICAL_SURFACE-0.264
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.222
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_011_TURBT_S228 | — | — | 0.887 |
| 2 | EDABB4DE-6443-4EA2-B64A-9C492D3F5A2C | — | — | 0.861 |
| 3 | TCGA-E2-A109-01A-11R-A10J-07 | — | B | 0.850 |
| 4 | SRR934937 | — | — | 0.844 |
| 5 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.837 |
| 6 | 74897E26-10A5-4484-A867-CE7C86DDB7E2 | — | — | 0.834 |
| 7 | SRR15069617 | — | — | 0.831 |
| 8 | 431EAB8C-D0B4-4440-A2B6-1D001B0026E2 | — | — | 0.830 |
| 9 | SRR934879 | — | — | 0.824 |
| 10 | cfda240e-d071-418b-9a7d-a6fd30e60cdf | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.715 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.672 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.645 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.603 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.312 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.301 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.279 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.275 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.223 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.175 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.145 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.134 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.132 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.115 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.086 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.062 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.049 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.037 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.033 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.005 | Idelalisib | — uncovered |